CRISPR Therapeutics recently presented new preclinical data at the ESGCT 2025 Annual Congress showing its investigational CTX460, using the SyNTase gene editing platform, achieved greater than 90% ...
One of the most revolutionary tools in cutting-edge medicine is a molecular scalpel so precise that it can modify defective ...
Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...
In May, a historic moment in science and medicine was captured in a single photo that circulated across news outlets ...
CRISPR Therapeutics’ stock is surging as in-vivo therapies show promise. Learn about CRSP stock's risks, long-term upside, ...
Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark Age predecessors, living until ripe old age and enjoying the fruits of our ...
Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...
The field of food microbiology has witnessed a transformative change with the advent of CRISPR technology, which offers ...
A CRISPR-Cas9-based therapy targeting the gene encoding transthyretin greatly reduced transthyretin levels in patients with ...
CRISPR Therapeutics (CRSP) saw its shares surge in the last session with trading volume being higher than average. The latest ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback